V 116517
Alternative Names: V-116517Latest Information Update: 23 Dec 2019
At a glance
- Originator Purdue Pharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal pain; Pain; Postherpetic neuralgia
Most Recent Events
- 23 Dec 2019 No development reported - Phase-II for Postherpetic neuralgia in USA (PO)
- 25 Aug 2015 No recent reports on development identified - Phase-II for Musculoskeletal pain in USA (PO)
- 01 Apr 2014 Purdue Pharma completes a phase II trial in Postherpetic neuralgia in USA (NCT01688947)